Drug Trial Radar · NCT02721433
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
Last checked: Nov 20, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
263
Actual
Start
Aug 2016
Primary completion
Sep 2019
Study completion Apr 2020
Sponsor
- Lead sponsor
- Ottawa Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs. 4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal events within the Canadian Health Care System. This study will use an "integrated consent model" that involves "oral consent" rather than a written informed consent writing process as the study is comparing standard schedules and not a new administration schedule.
Conditions
- Breast Cancer
- Prostate Cancer
- Metastasis
Interventions
PamidronateDrug
Bone-targeted agent as standard of care
DenosumabDrug
Bone-targeted agent as standard of care
ZoledronateDrug
Bone-targeted agent as standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Health related quality of life scores measured with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Functional Domain (Physical Subdomain)Time frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.